Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Germá-Lluch, J. R.
Right arrow Articles by Barnadas, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Germá-Lluch, J. R.
Right arrow Articles by Barnadas, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 10:289-293, 1999
© 1999 European Society for Medical Oncology

research-article

BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: The Spanish Germ-Cell Cancer Group experience (GG)

J. R. Germá-Lluch1, X. Garcia del Muro1, J. M. Tabernero2, M. S{acute}nchez3, J. Aparicio4, E. Alba5 and A. Barnadas6

1Institut Català d Òncologia; Barcelona
2Hospital de la Santa Creu i Sant Pau Barcelona
3Hospital Nuestra Sra, de Ar{acute}nzazu, San Sebasti{acute}n Valencia
4Hospital La Fe Valencia
5Hospital Clinico Universitario de Málaga Badalona, Spain
6Hospital Germans Trias i Pujol Badalona, Spain

Background: Patients with poor-prognosis germ-cell tumors according to the IGCCC have a poor long-term survival. This study evaluates the efficacy and toxicity of the intensive alternating chemotherapy regimen BOMP/EPI in these patients.

Patients and methods: Patients with IGCCC poor-prognosis germ-cell tumors treated at 13 centres were studied. Treatment consisted of bleomycin 30 mg, vincristine 2 mg, methotrexate 300 mg/m2 and cisplatin 100 mg/m2 (BOMP), alternating after a 14-day interval with etoposide 120 mg/m2 day 1-4, ifosfamide 1.3 g/m2 day 1–4 and cisplatin 25 mg/m2 day 1–4 (EPI). BOMP was administered 21 days after the EPI. Bleomycin was administered weekly per 12 weeks.

Results: Thirty-eight patients were treated. The median number of cycles administered was 7 (1–10 cycles). Eighteen patients achieved complete responses with chemotherapy alone (12 had necrosis and 2 mature teratoma at postchemotherapy resection), and four achieved complete responses with chemotherapy and surgical resection of viable cancer. Thus, an overall favorable response was achieved in 22 patients (60%). Four additional patients had marker-negative non-resected residual masses. Eleven patients were considered treatment failures, including one who died early and another who succumbed to granulocytopenic sepsis and renal failure. Hematologic toxicity was the most common, with 26 patients (70%) having grade 4 granulocytopenia. After a median follow-up of 41 months, the actuarial two-year overall survival and progression-free survival were 64% and 58%, respectively.

Conclusion: BOMP/EPI is active in poor-prognosis germ-cell tumors according to the IGCCC criteria. The results obtained compare favorably with those expected with conventional chemotherapy, and justify further studies.

BOMP/EPI, germ-cell, tumor, poor-prognosis, testicular cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
H.-J. Schmoll, C. Kollmannsberger, B. Metzner, J.T. Hartmann, N. Schleucher, P. Schoffski, J. Schleicher, O. Rick, J. Beyer, D. Hossfeld, et al.
Long-Term Results of First-Line Sequential High-Dose Etoposide, Ifosfamide, and Cisplatin Chemotherapy Plus Autologous Stem Cell Support for Patients With Advanced Metastatic Germ Cell Cancer: An Extended Phase I/II Study of the German Testicular Cancer Study Group
J. Clin. Oncol., November 15, 2003; 21(22): 4083 - 4091.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.